Department of Pharmaceutical Sciences, Northeastern University, Mailstop 206, 140TF 360 Huntington Avenue, Boston, MA 02115, USA.
J Pharmacol Exp Ther. 2013 Jan;344(1):8-14. doi: 10.1124/jpet.112.199331. Epub 2012 Sep 27.
In vivo effects of cannabinoid (CB) agonists are often assessed using four well-established measures: locomotor activity, hypothermia, cataleptic-like effects, and analgesia. The present studies demonstrate that doses of CB agonists that produce these effects also reliably increase diuresis. Diuretic effects of several CB agonists were measured in female rats over 2 hours immediately after drug injection, and results were compared with hypothermic effects. Direct-acting CB1 agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia. The highest doses of cannabinoid drugs yielded, on average, 26-32 g/kg urine; comparable effects were obtained with 10 mg/kg furosemide and 3.0 mg/kg trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50-488). Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects. In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl methanone)]. These data indicate that cannabinoids have robust diuretic effects in rats that are mediated via CB1 receptor mechanisms.
在体内,大麻素(CB)激动剂的作用通常通过四种成熟的方法来评估:运动活性、体温降低、类似瘫痪的作用和镇痛。本研究表明,产生这些作用的 CB 激动剂剂量也能可靠地增加利尿作用。在药物注射后立即的 2 小时内,在雌性大鼠中测量了几种 CB 激动剂的利尿作用,并将结果与体温降低作用进行了比较。直接作用的 CB1 激动剂,包括 Δ(9)-四氢大麻酚、WIN 55,212[R-(1)-[2,3-二氢-5-甲基-3-[(吗啉基)甲基]吡咯并[1,2,3-de]-1,4-苯并恶嗪基]-(1-萘基)甲酮甲磺酸盐]、AM2389[9β-羟基-3-(1-己基-环丁-1-基)-六氢大麻醇]和 AM4054[9β-(羟甲基)-3-(1-金刚烷基)-六氢大麻醇],产生了剂量依赖性的利尿作用和结肠温度降低作用,利尿作用的 ED50 值略低于体温降低作用。大麻素药物的最高剂量平均产生 26-32 g/kg 尿液;用 10 mg/kg 呋塞米和 3.0 mg/kg trans-(-)-3,4-二氯-N-甲基-N-[2-(1-吡咯烷基)环己基]苯乙酰胺(U50-488)也可获得可比的效果。甲酰胺(10.0 mg/kg)的作用小于其他 CB 激动剂,CB2 激动剂 AM1241[1-(甲基哌啶-2-基甲基)-3-(2-碘-5-硝基苯甲酰基)吲哚]、酰胺转运抑制剂 AM404 和 CB 拮抗剂利莫那班没有利尿作用。在进一步的研究中,CB1 激动剂 AM4054 在雄性和雌性大鼠中的利尿作用相似,表现出相对较快的作用起始,并且 30 分钟前用利莫那班预处理可剂量依赖性地拮抗,但用香草素受体 1 拮抗剂辣椒素不能拮抗,WIN 55,212 的作用也不能用 CB2 拮抗剂 AM630(6-碘-2-甲基-1-[2-(4-吗啉基)乙基]-1H-吲哚-3-基甲酮]拮抗。这些数据表明,大麻素在大鼠中具有强大的利尿作用,这是通过 CB1 受体机制介导的。